Literature DB >> 15770730

Synergistic effects of interferon-alpha in combination with chemoradiation on human pancreatic adenocarcinoma.

Jian-Hua Ma1, Emilia Patrut, Jan Schmidt, Hanns-Peter Knaebel, Markus W Büchler, Angela Märten.   

Abstract

AIM: To determine whether IFN-alpha is the agent that turns a slightly effective treatment (radiochemotherapy) into a potent therapy, we tested IFN-alpha for its synergistic properties.
METHODS: Eight pancreatic carcinoma cell lines were treated with the single agents and combinations of these. The role of IFN-alpha regarding a) direct inhibitory effects; b) radio and chemosensitizing effects; c) anti-angiogenic properties and d) enhancement of immunogenicity was investigated.
RESULTS: Our results show that IFN-alpha has direct inhibitory properties and some synergistic influence as determined by AnnexinV/PI stain and cell count. IFN-alpha is also able to prevent the increase in proliferation rate and VEGF secretion of CDDP resistant cells. Having taken the results from immunogenicity experiments together, we found cells that can be influenced by IFN-alpha but were less susceptible against T cells. Furthermore, high expression of MHC molecules, CD118, EGF-R and Fas was predictive for a good response.
CONCLUSION: In conclusion, IFN-alpha has direct cytotoxic effects, acts as a radiosensitizer and circumvents tumor cell-regrowth after CDDP treatment. These mechanisms may be responsible for the good clinical outcome of CapRI.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15770730      PMCID: PMC4305696          DOI: 10.3748/wjg.v11.i10.1521

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  25 in total

1.  Interferons inhibit EGF-stimulated cell growth and reduce EGF binding in human breast cancer cells.

Authors:  F Iacopino; G Ferrandina; G Scambia; P Benedetti-Panici; S Mancuso; G Sica
Journal:  Anticancer Res       Date:  1996 Jul-Aug       Impact factor: 2.480

Review 2.  Interferon-alpha in tumor immunity and immunotherapy.

Authors:  Filippo Belardelli; Maria Ferrantini; Enrico Proietti; John M Kirkwood
Journal:  Cytokine Growth Factor Rev       Date:  2002-04       Impact factor: 7.638

3.  Enhancement of radiation effects by alpha interferon in the treatment of small cell carcinoma of the lung.

Authors:  L R Holsti; K Mattson; A Niiranen; C G Standertskiöld-Nordenstam; S Stenman; A Sovijärvi; K Cantell
Journal:  Int J Radiat Oncol Biol Phys       Date:  1987-08       Impact factor: 7.038

4.  Treatment of colon and breast carcinoma cells with 5-fluorouracil enhances expression of carcinoembryonic antigen and susceptibility to HLA-A(*)02.01 restricted, CEA-peptide-specific cytotoxic T cells in vitro.

Authors:  Pierpaolo Correale; Angelo Aquino; Anna Giuliani; Monia Pellegrini; Lucia Micheli; Maria Grazia Cusi; Cristina Nencini; Roberto Petrioli; Salvatore Pasquale Prete; Liana De Vecchis; Mario Turriziani; Giorgio Giorgi; Enzo Bonmassar; Guido Francini
Journal:  Int J Cancer       Date:  2003-04-20       Impact factor: 7.396

5.  Interferon-alpha activates multiple STAT proteins and upregulates proliferation-associated IL-2Ralpha, c-myc, and pim-1 genes in human T cells.

Authors:  S Matikainen; T Sareneva; T Ronni; A Lehtonen; P J Koskinen; I Julkunen
Journal:  Blood       Date:  1999-03-15       Impact factor: 22.113

6.  Interferon-based adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma.

Authors:  Vincent J Picozzi; Richard A Kozarek; L William Traverso
Journal:  Am J Surg       Date:  2003-05       Impact factor: 2.565

7.  Mechanism of interferon alpha on inhibition of metastasis and angiogenesis of hepatocellular carcinoma after curative resection in nude mice.

Authors:  Lu Wang; Wei-Zhong Wu; Hui-Chuan Sun; Xiao-Feng Wu; Lun-Xiu Qin; Yin-Kun Liu; Kang-Da Liu; Zhao-You Tang
Journal:  J Gastrointest Surg       Date:  2003 Jul-Aug       Impact factor: 3.452

Review 8.  Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons.

Authors:  L M Pfeffer; C A Dinarello; R B Herberman; B R Williams; E C Borden; R Bordens; M R Walter; T L Nagabhushan; P P Trotta; S Pestka
Journal:  Cancer Res       Date:  1998-06-15       Impact factor: 12.701

Review 9.  Cancer immunotherapy: the interferon-alpha experience.

Authors:  John Kirkwood
Journal:  Semin Oncol       Date:  2002-06       Impact factor: 4.929

10.  Accelerated regrowth of non-small-cell lung tumours after induction chemotherapy.

Authors:  S Y El Sharouni; H B Kal; J J Battermann
Journal:  Br J Cancer       Date:  2003-12-15       Impact factor: 7.640

View more
  3 in total

1.  Oncolytic adenovirus expressing interferon alpha in a syngeneic Syrian hamster model for the treatment of pancreatic cancer.

Authors:  Christopher J LaRocca; Joohee Han; Tatyana Gavrikova; Leonard Armstrong; Amanda R Oliveira; Ryan Shanley; Selwyn M Vickers; Masato Yamamoto; Julia Davydova
Journal:  Surgery       Date:  2015-02-27       Impact factor: 3.982

2.  Chemoradiotherapy in pancreatic carcinoma.

Authors:  Sushmita Pathy; Subhash Chander
Journal:  Indian J Med Paediatr Oncol       Date:  2009-04

3.  A randomized multicentre phase II trial comparing adjuvant therapy in patients with interferon alpha-2b and 5-FU alone or in combination with either external radiation treatment and cisplatin (CapRI) or radiation alone regarding event-free survival - CapRI-2.

Authors:  Angela Märten; Jan Schmidt; Jennifer Ose; Sabine Harig; Ulrich Abel; Marc W Münter; Dirk Jäger; Helmut Friess; Julia Mayerle; Guido Adler; Thomas Seufferlein; Thomas Gress; Roland Schmid; Markus W Büchler
Journal:  BMC Cancer       Date:  2009-05-26       Impact factor: 4.430

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.